文献速递儿童青少年精神精神分裂症与精神病性障碍

ADHD药物治疗期间的精神病性症状:临床考量与研究需求

Psychotic symptoms during pharmacological treatment of ADHD: clinical considerations and research needs.
PubMed 文献 · Lancet Psychiatry · 2025-10-17

本文为一篇个人观点文章,探讨ADHD药物治疗期间可能出现的精神病性症状的预防与管理。当前证据不支持药物(至少哌甲酯)与精神病性症状存在因果关联。文章围绕用药前筛查、临床管理及研究重点提出建议。

要点

  • ADHD个体精神病性障碍发生风险显著升高,且独立于ADHD药物治疗。
  • 当前证据不支持ADHD药物(至少哌甲酯)与精神病性症状存在因果关联。
  • 需在用药前筛查精神病易感性,并权衡风险与药物治疗获益。

核心结论

  • 当前证据不支持ADHD药物(至少哌甲酯)与精神病性症状存在因果关联。
  • 文章提供了基于证据与临床实践的框架,以指导ADHD药物治疗期间精神病性症状的预防与管理。

研究设计与样本

  • 本文为Personal View(个人观点)文章,基于现有证据与临床实践进行论述。

主要发现

  • 当前证据不支持ADHD药物(至少哌甲酯)与精神病性症状存在因果关联。
  • ADHD个体对精神病易感性存在个体差异,处方ADHD药物时需平衡潜在风险(如精神病性症状出现)与药物治疗的已证实获益。

关键数值与推荐

  • 当前证据不支持ADHD药物(至少哌甲酯)与精神病性症状存在因果关联。

临床怎么用

  • 在启动ADHD药物治疗前,应筛查个体对精神病的易感性。
  • 处方ADHD药物时需平衡潜在风险(如精神病性症状出现)与药物治疗的已证实获益。
  • 对ADHD药物治疗期间可能出现的精神病性症状,应提供临床管理指导,包括考虑剂量和药物类型。

局限性

  • 本文为个人观点文章,非系统综述或原始研究,未报告检索策略或样本量等系统方法学信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this Personal View, we address key questions to support evidence-based prevention and management of psychotic symptoms that might occur during ADHD pharmacotherapy. We begin by examining evidence showing a significantly increased occurrence of psychotic disorders in individuals with ADHD, independent of ADHD medications (pooled relative risk, odds ratio, or hazard ratio=4·74, 95% CI 4·11-5·46). We then examine whether ADHD medications play a causal role, noting that current evidence does not support such a causal link, at least for methylphenidate. We explore how vulnerability to psychosis varies across individuals with ADHD. Regarding the different steps involved in prescribing ADHD medications, we discuss the importance of balancing potential risks-such as emergence of psychotic symptoms-against the demonstrated benefits of pharmacological treatment for ADHD. Next, we present strategies for screening individuals for vulnerability to psychosis before initiating ADHD medication. We then offer guidance on the clinical management of psychotic symptoms that might arise during ADHD pharmacotherapy, including considerations of dosage and medication type. Finally, we identify key research priorities in this area. Overall, this paper provides an empirical framework, grounded in evidence and clinical practice, to guide the next steps in the field.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cortese S, Garcia-Argibay M, Oliver D, et al. Psychotic symptoms during pharmacological treatment of ADHD: clinical considerations and research needs. Lancet Psychiatry. 2025. PMID: 41115444. doi:10.1016/S2215-0366(25)00248-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。